No…quite the opposite
Answered most non-holders issues
Also my impression is they read HC and made a point of countering
*Trial end point design in the Phase 3 trial
*Use of HA as a control and then as a carrier for the MSC’s
*Potency assays and use of data sets gleaned from both Rem-l and Rex-l for use in upcoming applications to FDA
*Future funding is being explored
Chronic Lower Back Pain - the sleeping giant., page-153
-
- There are more pages in this discussion • 332 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.0¢ |
Change
0.025(2.82%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 95.0¢ | 88.0¢ | $4.811M | 5.232M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3906 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 86.0¢ | 96052 | 5 |
View Market Depth
| Last trade - 15.59pm 06/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |